VYNE Stock Summary and Trading Ideas (Vyne Therapeutics | NASDAQ:VYNE)

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

Vyne Therapeutics trades on the NASDAQ stock market under the symbol VYNE.

As of February 7, 2025, VYNE stock price declined to $2.40 with 18,594 million shares trading.

VYNE has a beta of 1.91, meaning it tends to be more sensitive to market movements. VYNE has a correlation of 0.09 to the broad based SPY ETF.

VYNE has a market cap of $35.40 million. This is considered a Sub-Micro Cap stock.

Last quarter Vyne Therapeutics reported $121,000 in Revenue and -$.29 earnings per share. This beat revenue expectation by $11,000 and missed earnings estimates by -$.06.

In the last 3 years, VYNE traded as high as $14.22 and as low as $1.57.

The top ETF exchange traded funds that VYNE belongs to (by Net Assets): VTI, VXF, IWC.

VYNE has underperformed the market in the last year with a price return of +13.7% while the SPY ETF gained +23.7%. VYNE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -23.3% and -10.1%, respectively, while the SPY returned +2.5% and -0.9%, respectively.

VYNE support price is $2.22 and resistance is $2.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VYNE shares will trade within this expected range on the day.